Pfizer Inc. (PFE) income statement
NYSE · Healthcare · Drug Manufacturers - General · 75,000 employees · CEO Albert Bourla
- Price
- $30.52 +1.90%
- Market cap
- $174B
- Enterprise value
- $236B
- Last report
- Q2 '26 filed 2026-08-04
- Next report
- 2026-11-03 EPS est. $0.73
Pfizer Inc. (PFE) reported revenue of $15B for Q2 '26 (+2.6% year on year), operating income of $3.54B (23.5% of revenue) and net income of -$248M. Over the last four quarters revenue was $63.7B.
Income statement
| Income statement | Trend | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.5B | $14.2B | $14.9B | $13.3B | $17.7B | $17.8B | $13.7B | $14.7B | $16.7B | $17.6B | $14.5B | $15B | |
| Cost of revenue | $9.27B | $7.56B | $3.38B | $3.3B | $5.26B | $5.91B | $2.85B | $3.78B | $4.17B | $5.27B | $3.55B | $4.09B | |
| Gross profit | $4.22B | $6.69B | $11.5B | $9.98B | $12.4B | $11.9B | $10.9B | $10.9B | $12.5B | $12.3B | $10.9B | $10.9B | |
| Research & development | $2.71B | $2.82B | $2.49B | $2.7B | $2.61B | $3.04B | $2.2B | $2.48B | $2.55B | $3.21B | $2.49B | $2.81B | |
| Other operating expenses | $1.18B | $1.27B | $1.31B | $1.31B | $1.31B | $1.36B | $1.21B | $1.21B | $1.22B | $1.23B | $1.18B | $1.19B | |
| Operating expenses | $7.17B | $8.66B | $7.3B | $7.73B | $7.17B | $8.67B | $6.45B | $7.11B | $6.96B | $8.6B | $6.63B | $7.41B | |
| Operating income | -$2.95B | -$1.97B | $4.2B | $2.26B | $5.27B | $3.19B | $4.43B | $3.77B | $5.53B | $3.69B | $4.27B | $3.54B | |
| Interest income | $523M | $609M | $129M | $130M | $116M | $170M | $143M | $156M | $138M | $166M | $115M | $113M | |
| Interest expense | $695M | $689M | $790M | $778M | $783M | $739M | $654M | $654M | $652M | $711M | $668M | $667M | |
| Other non-operating income (gains on investments, FX ...) | -$291M | $1.47B | -$8M | $1.58B | -$227M | $2.46B | $986M | $69M | $1.54B | $4.62B | $430M | $3.52B | |
| Total non-operating income | -$404M | -$2.16B | -$782M | -$2.36B | -$556M | -$3.2B | -$1.64B | -$723M | -$2.19B | -$5.33B | -$1.1B | -$4.19B | |
| Income before tax | -$3.35B | -$4.13B | $3.42B | -$103M | $4.72B | -$10M | $2.79B | $3.04B | $3.33B | -$1.64B | $3.17B | -$653M | |
| Income tax | -$964M | -$795M | $293M | -$134M | $234M | -$421M | -$188M | $141M | -$216M | -$2M | $461M | -$407M | |
| Net income | -$2.38B | -$3.37B | $3.12B | $41M | $4.47B | $410M | $2.97B | $2.91B | $3.54B | -$1.65B | $2.69B | -$248M | |
| EPS (basic) | -$0.42 | -$0.60 | $0.55 | $0.00 | $0.79 | $0.07 | $0.52 | $0.51 | $0.62 | -$0.29 | $0.47 | -$0.04 | |
| EPS (diluted) | -$0.42 | -$0.60 | $0.55 | $0.00 | $0.78 | $0.07 | $0.52 | $0.51 | $0.62 | -$0.29 | $0.47 | -$0.04 | |
| Shares (basic, weighted) | 5.65B | 5.65B | 5.66B | 5.67B | 5.67B | 5.67B | 5.68B | 5.69B | 5.69B | 5.68B | 5.69B | 5.7B | |
| Shares (diluted, weighted) | 5.65B | 5.65B | 5.7B | 5.7B | 5.71B | 5.7B | 5.71B | 5.71B | 5.71B | 5.69B | 5.73B | 5.7B | |
| Depreciation & amortization | $1.56B | $1.67B | $1.74B | $1.73B | $1.76B | $1.79B | $1.62B | $1.63B | $1.66B | $1.69B | $1.61B | $1.62B | |
| EBITDA | -$1.1B | -$1.77B | $5.95B | $2.41B | $7.25B | $2.52B | $5.06B | $5.32B | $5.65B | $756M | $5.45B | $1.64B |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.8B | $52.5B | $40.8B | $40.9B | $41.7B | $81.3B | $101B | $59.6B | $63.6B | $62.6B | |
| Cost of revenue | $12.3B | $11.2B | $8.99B | $8.05B | $8.48B | $30.8B | $34.3B | $25B | $17.9B | $16.1B | |
| Gross profit | $40.5B | $41.3B | $31.8B | $32.9B | $33.2B | $50.5B | $66.8B | $34.6B | $45.8B | $46.5B | |
| Research & development | $7.89B | $7.68B | $7.76B | $8.39B | $9.39B | $13.8B | $11.4B | $10.7B | $10.8B | $10.4B | |
| Other operating expenses | $4.06B | $4.76B | $4.74B | $4.43B | $3.35B | $3.7B | $3.61B | $4.73B | $5.29B | $4.87B | |
| Operating expenses | $26.8B | $27.2B | $25.1B | $25.5B | $24.3B | $30.2B | $28.7B | $30.2B | $30.8B | $29.1B | |
| Operating income | $13.7B | $14.1B | $6.73B | $7.31B | $8.83B | $20.2B | $38.1B | $4.42B | $14.9B | $17.4B | |
| Interest income | $470M | $391M | $333M | $225M | $73M | $36M | $251M | $1.62B | $545M | $603M | |
| Interest expense | $1.19B | $1.27B | $1.32B | $1.57B | $1.45B | $1.29B | $1.24B | $2.21B | $3.09B | $2.67B | |
| Other non-operating income (gains on investments, FX ...) | $4.17B | $498M | $1.82B | -$5.58B | $344M | -$5.37B | $2.15B | $1.15B | $3.82B | $7.22B | |
| Total non-operating income | -$5.36B | -$1.77B | -$3.14B | $4.01B | -$1.79B | $4.08B | -$3.39B | -$3.36B | -$6.92B | -$9.89B | |
| Income before tax | $8.35B | $12.3B | $3.59B | $11.3B | $7.04B | $24.3B | $34.7B | $1.06B | $8.02B | $7.52B | |
| Income tax | $1.12B | -$9.05B | -$266M | $583M | $370M | $1.85B | $3.33B | -$1.12B | -$28M | -$266M | |
| Net income | $7.22B | $21.3B | $11.2B | $16B | $9.16B | $22B | $31.4B | $2.12B | $8.03B | $7.77B | |
| EPS (basic) | $1.18 | $3.57 | $1.90 | $2.92 | $1.65 | $3.95 | $5.59 | $0.38 | $1.42 | $1.36 | |
| EPS (diluted) | $1.17 | $3.52 | $1.87 | $2.87 | $1.63 | $3.88 | $5.47 | $0.37 | $1.41 | $1.36 | |
| Shares (basic, weighted) | 6.09B | 5.97B | 5.87B | 5.57B | 5.56B | 5.6B | 5.61B | 5.64B | 5.66B | 5.68B | |
| Shares (diluted, weighted) | 6.16B | 6.06B | 5.98B | 5.68B | 5.63B | 5.71B | 5.73B | 5.71B | 5.7B | 5.69B | |
| Depreciation & amortization | $5.76B | $6.27B | $6.15B | $5.76B | $4.78B | $5.19B | $5.06B | $6.29B | $7.01B | $6.59B | |
| EBITDA | $15.3B | $19.8B | $11.1B | $18.6B | $13.3B | $30.8B | $41B | $9.56B | $18.1B | $16.8B |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-28, 10-Q 2026-03-29, 10-K 2025-12-31, 10-Q 2025-09-28, 10-Q 2025-06-29, 10-Q 2025-03-30, 10-K 2024-12-31, 10-Q 2024-09-29, 10-Q 2024-06-30
Data as of 2026-11-01